Please login to the form below

Not currently logged in
Email:
Password:

Glythera strengthens its scientific advisory board and appoints CSO

Dr Robert Lutz and Dr Jon Roffey join the UK biotech

Robert Lutz Glythera has appointed new chief scientific officer Dr Robert Lutz to lead the advancement of the UK-based biotech's antibody drug conjugate portfolio.

Dr Lutz was previously vice president of translation research and development at ImmunoGen, where he was responsible for all early-stage ADC development programmes.

Additionally, Dr Jon Roffey joins Glythera’s scientific advisory board (SAB) from Cancer Research Technology (CRT), Cancer Research UK’s commercial partnerships team, where he had been working since 2006.

Dr Dave Simpson, chief executive officer of Glythera, said: “Robert Lutz’s experience in ADC development will be a great asset as Glythera continued to develop our pipeline of cancer treatments.

“With his appointment as CSO, and the addition of Jon to our SAD, we start 2018 in a strengthened position as developers of the very best novel agents and targeted treatments, aiming to improve the lives of patients living with cancers that are the hardest to treat.”

23rd January 2018

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics